Trump administration poised to tie Tylenol to autism risk, explore leucovorin therapy, sources say

WASHINGTON — The Trump administration is set to announce on Monday that using Tylenol during pregnancy could raise the risk of autism, according to the New York Post. The plan calls for advising pregnant women to avoid acetaminophen except in cases of high fever, and for officials to outline investigations into using leucovorin, a cancer and anemia drug, as a possible autism treatment. The announcements are part of a broader push by the administration to tie a widely used over-the-counter medication to developmental outcomes while presenting potential therapies.

Sources familiar with the plan told the Post that the messaging will draw on data from ongoing studies and the Centers for Disease Control and Prevention's Autism and Developmental Disabilities Monitoring Network. HHS Secretary Robert F. Kennedy Jr. was prepared to discuss the ADDM findings in remarks scheduled in conjunction with the announcement. The plan underscores the administration’s effort to frame Tylenol exposure as a possible autism risk while positioning leucovorin as a potential treatment option under study.

Trump has publicly teased a major announcement, saying during a weekend speech at conservative influencer Charlie Kirk’s funeral that, "I think we found an answer to autism," and that it would be "one of the most important news conferences I’ll ever have, and I look so forward to it."

Leucovorin, a drug commonly used to treat certain cancers and anemia, was described by officials as a candidate for exploring autism treatment as part of the administration’s broader research push. The plan envisions coordinating with researchers to assess whether the drug could help some individuals on the autism spectrum, though no definitive results were announced.

Officials have not publicly disclosed the full scope of the rollout, and requests for comment were not immediately returned.